Gossamer Bio, Inc.
GOSS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$9.61
KIRA · Stoqly’s AI analyst, in plain words
- Gossamer Bio, Inc. had $48.5M of revenue in fiscal 2025, down 57.7% on the year before.
- Its operating margin was −352.2%, down 300.0 pts: of every 100 in sales, about −352 is left after running the business.
- Gossamer Bio, Inc. lost $170M in fiscal 2025.
- Free cash flow was −$171M in fiscal 2025, −353.5% of revenue.
Market cap
$3.2B
P/E
—
Revenue
$48.5M
Net income
−$170M
Free cash flow
−$171M
Operating margin
−352.2%
Gossamer Bio, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−57.7%
No. Sales fell 57.7% last year.
Does it make a profit?
−351.5%
No. It lost money last year.
Does profit turn into cash?
−353.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
0 / 7
Weak. It passes 0 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Gossamer Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- Gossamer Bio, Inc.
- CIK
- 0001728117
Gossamer Bio, Inc. · GOSS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $0.0M | $115M | $48.5M |
| Revenue growth | — | — | — | — | −57.7% |
| Operating margin | — | — | — | −52.2% | −352.2% |
| Net income | −$234M | −$229M | −$180M | −$56.5M | −$170M |
| Net margin | — | — | — | −49.3% | −351.5% |
| Diluted EPS | −$3.13 | −$2.71 | −$1.18 | −$0.25 | −$0.75 |
| Cash | |||||
| Cash from operations | −$189M | −$187M | −$159M | −$3.5M | −$171M |
| Capital expenditure | $1.5M | $0.4M | $0.0M | $0.0M | $0.1M |
| Free cash flow | −$190M | −$187M | −$159M | −$3.5M | −$171M |
| FCF margin | — | — | — | −3.0% | −353.5% |
| Share count change | 9.2% | 13.0% | 80.5% | 48.2% | 1.0% |
| Debt and strength | |||||
| Cash and short-term investments | $325M | $256M | $296M | $295M | $137M |
| Debt incl. finance leases | $29.1M | $23.6M | $12.4M | $0.0M | — |
| Shareholders' equity | $121M | $12.1M | $62.8M | $29.5M | −$123M |
| Current ratio | 8.3x | 5.3x | 5.9x | 6.9x | 2.6x |
| Interest coverage | −11.1x | −15.7x | −13.6x | −5.2x | −15.5x |
| Returns and quality | |||||
| Return on equity | −105.8% | −343.5% | −480.5% | −122.5% | — |
| Return on tangible equity | −192.7% | −1,899.3% | −286.5% | −191.7% | — |
| Piotroski F-score | 1 | 1 | 4 | 5 | 0 |
| Altman Z'' | −5.8 | −12.6 | −11.0 | −8.8 | −30.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Gossamer Bio, Inc. · GOSS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.61 a share, the company is worth $3.2B.
Source: SEC EDGAR XBRL filings (CIK 0001728117). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.